Allied Market Research published a report, titled, "Cytogenetics Market by Product (Consumable, Instrument, Software and Service), by Technique (Comparative Genome Hybridization, Fluorescence in Situ ...

The technology, FISH-scRACS-seq (Fluorescence In Situ Hybridization-guided Single-Cell Raman-activated Sorting and Sequencing), utilizes a Raman-activated optical tweezers-based cell sorter ...

Molecular Instruments® (MI), founded by the inventor of the HCR technology, today announces the launch of the HCR Gold and HCR Pro product lines. These offerings significantly expand the HCR imaging ...

The integration will enable Leica’s BOND staining systems to simultaneously detect RNA and protein targets on the same tissue.

The "Bladder Cancer Diagnostics Market by Test Type, by Stages, by Cancer Type, by End User, and By Region" report has been ...

The global fluorescent in situ hybridization (FISH) probe market size was valued at $0.9 billion in 2023, and is projected to reach $1.8 billion by 2033, growing at a CAGR of 7.4% from 2024 to 2033.

in order to investigate the efficacy and tolerance of trastuzumab in combination with paclitaxel and carboplatin in patients with HER2-positive (fluorescence in situ hybridization [FISH] positive ...

The PATHWAY HER2 (4B5) test, the first and only FDA approved companion diagnostic for assessing HER2-low status since 2022, ...

Roche has announced that the FDA has expanded the approval of its PATHWAY® HER2/neu (4B5) Rabbit Monoclonal Primary Antibody test to identify HE ...